Study wrapper · #939
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
Pallavi K, Chandra A, Kumar K, et al. Maedica. 2025.
DOI: 10.26574/maedica.2025.20.4.824PubMed: 41537067
Editor's note
This systematic review pools eight randomized trials and reports substantial glycemic and weight reductions with retatrutide in a comorbid CKD population, plus a signal toward reduced albuminuria. An interesting dose-response pattern is noted, with lower doses appearing more effective for glycemic control. Gastrointestinal tolerability is the main safety consideration.
Plain-language abstract
A meta-analysis of eight trials found that retatrutide was associated with meaningful reductions in HbA1c and body weight in people with diabetes and/or obesity who also had chronic kidney disease, with mostly gastrointestinal side effects.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026